What are the recommended colon cancer screening guidelines for average‑risk individuals, including the age to start, preferred screening modality, interval, and age to stop?

Colon Cancer Screening Guidelines for Average-Risk Adults

For average-risk adults, begin colorectal cancer screening at age 45 years, with high-quality colonoscopy every 10 years or annual FIT as first-tier options, and consider stopping screening at age 75 years or when life expectancy is less than 10 years. 1

When to Start Screening

Ages 45-49 Years

• Offer screening to all average-risk individuals starting at age 45 years (weak recommendation based on low-quality evidence, but reflects updated guidance from the U.S. Multi-Society Task Force) 1
• The USPSTF also recommends starting at age 45 years, driven by increasing colorectal cancer incidence in younger birth cohorts 2
• Note: The American College of Physicians takes a more conservative stance, suggesting clinicians consider not screening ages 45-49 and instead discuss the uncertainty around benefits and harms in this age group 3

Age 50 and Older

• For those who have not initiated screening before age 50, strongly recommend screening beginning at age 50 (strong recommendation, high-quality evidence) 1
• This represents the most robust evidence base with well-established mortality reduction from randomized trials 2

Screening Test Options

First-Tier Tests (Strongly Recommended)

• High-quality colonoscopy every 10 years (strong recommendation, moderate-quality evidence) 1
  • Must be complete to cecum with photo-documentation
  • Adequate bowel preparation required
  • Performed by colonoscopist with ≥25% adenoma detection rate 1
• Annual fecal immunochemical test (FIT) (strong recommendation, moderate-quality evidence) 1

Second-Tier Tests (Acceptable Alternatives)

For patients who decline colonoscopy and FIT:

• Flexible sigmoidoscopy every 5-10 years (strong recommendation, high-quality evidence) 1
• CT colonography every 5 years (strong recommendation, low-quality evidence) 1
• FIT-fecal DNA (stool DNA) every 3 years (strong recommendation, low-quality evidence) 1

Third-Tier Tests (Limited Role)

• Capsule colonoscopy every 5 years only when patients decline all other options (weak recommendation, low-quality evidence) 1

Tests NOT Recommended

• The American College of Physicians explicitly recommends against stool DNA, CT colonography, capsule endoscopy, urine, or serum screening tests 3
• This creates some divergence from Multi-Society Task Force recommendations, reflecting different evidence thresholds

When to Stop Screening

Age 75 Years

• Consider stopping screening at age 75 years in individuals who are up-to-date with screening and have negative prior tests, particularly high-quality colonoscopy (weak recommendation, low-quality evidence) 1
• Also stop when life expectancy is less than 10 years 1
• The USPSTF recommends selective screening ages 76-85 based on individual patient factors 2

Ages 76-85 Years

• For persons without prior screening, consider screening up to age 85 depending on age and comorbidities (weak recommendation, low-quality evidence) 1
• Decision should incorporate health status, prior screening history, and patient preferences 1
• Evidence shows individuals with a prior negative colonoscopy 10+ years before reaching ages 76-85 have low colorectal cancer risk and are less likely to benefit from further screening 4

Age 86 and Older

• Do not screen - evidence on benefits and harms is lacking, and competing mortality likely precludes survival benefit 2

Important Caveats and Pitfalls

Quality Matters for Colonoscopy

• Colonoscopy is only first-tier when performed with high quality standards: complete cecal intubation, adequate prep, and by an endoscopist with ≥25% adenoma detection rate 1
• Poor quality colonoscopy loses its effectiveness advantage

Screening Disparities

• Black adults have the highest colorectal cancer incidence (43.6 per 100,000) and mortality (18.0 per 100,000) compared to all other racial/ethnic groups 2
• These disparities are primarily driven by inequities in access to and quality of screening and treatment, not genetic differences 2
• Ensure equitable access to screening, particularly in medically underserved populations 1

Resource Considerations

• Lowering the screening age to 45 increases demand on colonoscopy capacity and may create wait times for diagnostic procedures 5
• The U.S. has sufficient colonoscopy capacity to support screening ages 45-49, though equitable access remains uncertain 1

Guideline Divergence

• The American College of Physicians recommends starting at age 50 (not 45) and uses more conservative evidence thresholds than the Multi-Society Task Force and USPSTF 3
• In practice, the Multi-Society Task Force and USPSTF recommendations (starting at age 45) represent the current standard of care and are supported by insurance coverage 6